CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene

Biochemical and Biophysical Research Communications

Volumn 443, Issue 1, 2014, Pages 144-149

  Kumar, Pritesh ^a   Song, Zhao Hui ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Bazedoxifene; Cannabinoid receptor; Inverse agonist; Lasofoxifene; Selective estrogen receptor modulator

Indexed keywords

BAZEDOXIFENE; CANNABINOID 2 RECEPTOR; LASOFOXIFENE;

ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL;

BAZEDOXIFENE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR 1; CANNABINOID RECEPTOR 2; CB1; CB2; FDA; FOOD AND DRUG ADMINISTRATION; G PROTEIN-COUPLED RECEPTOR; GPCR; HOMOGENOUS TIME RESOLVED FLUORESCENCE; HTRF; INVERSE AGONIST; LASOFOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SERM;

BENZOXAZINES; CYCLIC AMP; DRONABINOL; DRUG INVERSE AGONISM; HEK293 CELLS; HUMANS; INDOLES; MORPHOLINES; NAPHTHALENES; PYRROLIDINES; RECEPTOR, CANNABINOID, CB2; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES;

EID: 84890857850     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.11.071     Document Type: Article

References (23)

1. Riggs B.L., Hartmann L.C. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N. Engl. J. Med. 2003, 348:618-629.
2. Maximov P.Y., Lee T.M., Jordan V.C. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr. Clin. Pharmacol. 2013, 8:135-155.
3. Stump A.L., Kelley K.W., Wensel T.M. Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. Ann. Pharmacother. 2007, 41:833-839.
4. Gennari L., Merlotti D., Martini G., Nuti R. Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. Expert Opin. Investig. Drugs 2006, 15:1091-1103.
5. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
6. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
7. Howlett A.C. Cannabinoid receptor signaling. Handb. Exp. Pharmacol. 2005, 53-79.
8. Pertwee R.G. Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol. 2005, 1-51.
9. Riether D. Selective cannabinoid receptor 2 modulators: a patent review 2009 - present. Expert Opin. Ther. Pat. 2012, 22:495-510.
10. Marriott K.S., Huffman J.W. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr. Top. Med. Chem. 2008, 8:187-204.
11. Adams C.P., Brantner V.V. Estimating the cost of new drug development: is it really 802million dollars?. Health Aff. 2006, 25:420-428.
12. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22:151-185.
13. Carley D.W. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs, Part II. IDrugs 2005, 8:310-313.
14. Carley D.W. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs, Part I. IDrugs 2005, 8:306-309.
15. Kumar P., Song Z.H. Identification of raloxifene as a novel CB2 inverse agonist. Biochem. Biophys. Res. Commun. 2013, 435:76-81.
16. Feng W., Song Z.H. Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor. Biochem. Pharmacol. 2003, 65:1077-1085.
17. Nebane N.M., Kellie B., Song Z.H. The effects of charge-neutralizing mutation D6.30N on the functions of CB1 and CB2 cannabinoid receptors. FEBS Lett. 2006, 580:5392-5398.
18. Song Z.H., Feng W. Absence of a conserved proline and presence of a conserved tyrosine in the CB2 cannabinoid receptor are crucial for its function. FEBS Lett. 2002, 531:290-294.
19. Song Z.H., Slowey C.A., Hurst D.P., Reggio P.H. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol. Pharmacol. 1999, 56:834-840.
20. Silverman S.L., Christiansen C., Genant H.K., Vukicevic S., Zanchetta J.R., de Villiers T.J., Constantine G.D., Chines A.A. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J. Bone Miner. Res. 2008, 23:1923-1934.
21. Cummings S.R., Ensrud K., Delmas P.D., LaCroix A.Z., Vukicevic S., Reid D.M., Goldstein S., Sriram U., Lee A., Thompson J., Armstrong R.A., Thompson D.D., Powles T., Zanchetta J., Kendler D., Neven P., Eastell R. Lasofoxifene in postmenopausal women with osteoporosis. N. Engl. J. Med. 2010, 362:686-696.
22. Idris A.I., Sophocleous A., Landao-Bassonga E., van't Hof R.J., Ralston S.H. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 2008, 149:5619-5626.
23. Lunn C.A., Reich E.P., Fine J.S., Lavey B., Kozlowski J.A., Hipkin R.W., Lundell D.J., Bober L. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br. J. Pharmacol. 2008, 153:226-239.